The rainbow trout has been utilized as a model for human carcinogenesis for a number of years. Trout are relatively inexpensive to maintain and exhibit (over the 9-12-month tumor assay period) very low spontaneous tumor backgrounds. One of the most powerful applications of this model is the design and conduct of large-scale tumor studies requiring thousands of animals that address statistically challenging questions of dose-response. Two recent examples of such applications include our studies on I3C as a tumor promoter and DBP as a tumor initiator. I3C was shown to promote AFB 1 -initiated liver cancer at doses near those recommended for supplementation in humans. Further studies are required to determine if the mechanisms responsible for promotion in trout can be extrapolated to humans. In the second example, we report results from the largest animal tumor study ever conducted. A total of 42,000 trout were utilized to measure DBP carcinogenesis down to incidences of 1 in 5,000. The dose response model deviated significantly from linearity although the existence of a threshold could not be statistically established. Extrapolation of the data model predicts a DBP dose producing 1 in 10 6 cancers that is 1,000-fold higher than predicted by the conservative linear model. If these results can be confirmed with other carcinogens (genotoxic and perhaps nongenotoxic) and other targets, this could have a significant impact on the utilization of animal tumor data in human risk assessment.
INTRODUCTION
Rainbow trout have a number of advantages as models of human carcinogenesis including sensitivity to important known or probable human carcinogens such as aflatoxins, nitrosamines, and polycyclic aromatic hydrocarbons (PAHs) (2, 3) . The purchase and per diem costs are a fraction of that for rodents. In addition, the spontaneous liver tumor incidence at 9-12 months in trout is approximately 0.1%. Studies over the years have shown that many mechanisms important to carcinogenesis are similar in trout and mammals, eg, pathways for metabolic activation, production of mutagenic DNA adducts, activation of oncogenes, etc (2, 3) . The one notable exception is that trout are relatively deficient in repair of global genomic DNA bulky adducts, a property that may enhance the sensitivity of the model (4) . The low cost, high responsiveness and low background incidence of this trout tumor model makes it an excellent choice for conducting statistically challenging studies addressing low dose-response questions that would simply not be practical with other animal models. We present two such recent applications. The first addresses the important question of the potency of indole-3-carbinol (I3C) as a tumor promoter (21) , and the second study is a low dose study with dibenzo[a,l]pyrene (DBP).
I3C ( Figure 1 ) is a phytochemical found in cruciferous vegetables including broccoli, brussels sprouts, and cauliflower, formed from glucobrassicin by the enzyme myrosinase (18) . I3C is an effective chemopreventive agent in a number of animals models, including trout, when administered prior to and/or concurrent with the carcinogen under test (6, 9, 13, 16, 19, 20) . I3C is a component of the human diet, is a top-10 selling dietary supplement and is being considered for the chemoprevention of breast cancer in healthy women (26) . However, we demonstrated some years ago that long-term postinitiation dietary treatment with I3C promoted liver cancer (1, 7, 21) . I3C promotes cancer in other animals and in other tissues (14, 15, 25) . Recently, I3C was examined in a rat multi-organ model to determine if there was a dose of I3C that protected the breast without enhancing risk for the liver (25) . The results from this study suggested that there might not be such a safe dose, at least in this model. These studies agreed with our work in the trout that suggested that the promotional potency of I3C was at least as great as its potency as an anti-initiating agent (1, 21) . For these reasons, it is very important to establish the relative risks, as well as the benefits, from long-term supplementation.
The risk assessment for chemical carcinogenesis has, as its regulatory target, exposures that would result in 1 additional cancer in 10 6 . The largest dose-response tumor study in a rodent model used 24,000 animals and resulted in identification of doses leading to 1 additional cancer in 10 2 mice (8). We have taken advantage of the trout model to design and conduct a 42,000-trout study to measure the dose response of dietary exposures to DBP with a target of identifying an additional 1 cancer in 10 3 animals, an order of magnitude improvement of the "mega-mouse" study. DBP is the most potent polycyclic aromatic hydrocarbon (PAH) carcinogen in animal models, including trout, and is present in the environment, making it an excellent choice for study of PAH carcinogenesis at low dose (10, 12, 23) . The results from this trout "ED001 study" exceeded our expectations and we where able to model the data to an incidence above background of 1 cancer in 5 × 10 3 trout.
I3C Potency as a Tumor Promoter:
The complete methodology and results from this tumor study were reported by FIGURE 2.-Promotional potency of dietary indole-3-carbinol on aflatoxin B 1 -initiated hepatocarcinogenesis in rainbow trout. The data are expressed as the 95% confidence limits for the odds ratio of tumor incidence vs control. The odds ratios for 0, 250, 500, 750, and 1,000 ppm I3C were 1, 1.15, 1.30, 2.00, and 4.34, respectively. Each I3C dietary group represent tumor incidence data from 1,234-1,646 trout. This data are taken from Oganesian et al (21) .
Oganesian et al (21) in 1999. Rainbow trout were initiated as embryos via a bath exposure to 0, 25, 50, 100, 175, or 250 ppb AFB 1 for 30 minutes. After hatching, trout were fed Oregon test diet (17) for 3 months and then randomly assigned to I3C dietary treatment groups of 0, 250, 500, 750, 1,000 or 1,250 ppm. The experimental diets were administered ad lib until the trout were 11-13 months of age at which time they were euthanized (with an overdose of buffered MS-222 as approved by the OSU IACUC) and examined by gross pathology. The livers were fixed and tumors confirmed histologically as described previously (11) . The lowest dose of I3C that significantly increased the tumor incidence odds ratio was 500 ppm (Figure 2 ). In addition to tumor incidence, there was a dose-dependent increase in tumor multiplicity (number of tumors in animals with tumors) (21) . At the rate of diet consumption, 500 ppm represents an average daily dose of 14-28 mg I3C/Kg body weight. For comparison, 1 supplier of I3C supplements (Life Extension) recommends daily doses as high as 10 mg/Kg. The results with the trout model would thus indicate that long-term supplementation with I3C could pose a significant risk to humans.
In this same tumor promotion study, we tested 2 hypotheses concerning the mechanism of action of I3C. When administered orally, I3C undergoes a series of condensation reactions in the stomach to produce dimers, trimers, and tetramers, 60 WILLIAMS ET AL TOXICOLOGIC PATHOLOGY some of which are effective ligands for the aryl hydrocarbon receptor (AHR) (5) . In addition, we have found that I3C is estrogenic in trout. Administration of I3C in the diet markedly induces the levels of vitellogenin in trout plasma (21) . This induction was blocked by tamoxifen, suggesting that it was estrogen receptor (ER)-dependent. Further studies point to the importance of the dimer of I3C, 3,3 -diindolylmethane, as an important mediator in vivo of I3C estrogenicity (24). As we had prior evidence that AHR ligands and estrogens could promote liver cancer in the trout model, we sought to address the importance of these pathways in the above I3C dose-response promotion study. Induction of vitellogenin was readily apparent at the lowest promotional dose of I3C (500 ppm), whereas CYP1A induction (a biomarker of AHR) was not apparent until 1,250 ppm (21) . We concluded that, at low dietary levels of I3C, estrogenic mechanisms of liver tumor promotion predominated, whereas, both ER-and AHRdependent mechanisms were effective at higher levels.
Low Dose Tumor Results with DBP:
Fingerling rainbow trout were administered the polycyclic aromatic hydrocarbon DBP (Figure 3 ) in the diet at doses of 0, 0.45, 1.27, 3.57, 10.1, 28.4, 80, and 225 ppm for a period of 4 weeks. All of the trout were subsequently fed control diet for 9 months prior to euthanasia and necropsy. Twenty-five trout from each group were sampled 15 or 29 days after the start of the experimental diets and DBP-DNA adducts measured by 33 P-postlabeling. DBP is a multi-organ carcinogen in trout producing tumors of the liver, stomach, kidney, and swim bladder (10, 23) . Only the results on DBP initiated hepatocarcinogenesis are discussed here. The DBP-DNA adduction in liver was linear down to lowest dose. However, the tumor incidence when measured as log % tumor incidence vs log DBP dose exhibited a significant negative departure from linearity with decreasing dose. A linear fit, which is the conservative extrapolation used in carcinogen risk assessment, could be rejected. A tumor incidence of 0.02% (1 in 5,000) was the lowest observable, an increase in sensitivity of 50-fold over the largest rodent study. The 95% confidence intervals at the two lowest DBP doses include a zero-response, however, this does not prove the existence of a threshold. Using the low-dose tumor data from this "mega trout" study, an extrapolation of the DBP dose required to produce 1 cancer in 10 6 is 1,000-fold higher than the currently used conservative linear model of extrapolation. Although these results represent a single carcinogen in a single model, the potential implications for the field of risk assessment for human carcinogenesis is significant.
SUMMARY
The rainbow trout (Oncorhynchus mykiss) has been successfully utilized as a nonmammalian tumor model for a number of years. Recently, we have exploited one of the advantages of this model, that is the ability to conduct studies with large sample sizes (thousands of animals), to address statistically challenging questions of dose-response in initiation and promotion of cancer. Two recent examples of the power of this model include a study on promotion of liver cancer by indole-3-carbinol (I3C), and a study of the potency of dibenzo[a,l]pyrene (DBP) as a initiator at doses producing incidences of 1 cancer per 5,000 animals. In both cases, we also addressed hypotheses concerning the mechanism(s) of action.
We conducted a study using 9,000 trout, examining hepatocarcinogenesis at multiple dietary doses of I3C fed for a period of 8-10 months over a wide range of aflatoxin B 1 (AFB 1 ) doses. I3C, at dietary levels as low as 500 ppm, promoted liver tumors across the entire dose range of AFB 1 . We were not able to statistically demonstrate the existence of a threshold. The lowest dose of I3C tested (250 ppm) promoted AFB 1 at some, but not all, doses. At least two promotional mechanisms are thought to be in effect, one acting through the estrogen receptor (ER) and the other through the aryl hydrocarbon receptor (AHR). ER-dependent promotion seems to predominant at low I3C exposures.
DBP is a carcinogen with multiple target tissues in the trout model. In the largest cancer study done in any animal model (this paper provides a summary of this as yet unpublished study), 42,000 trout were utilized in an attempt to extrapolate the dose-response of a chemical carcinogen to 1 additional tumor in 10 3 animals, at least an order of magnitude improvement over any cancer study in a mammalian model. DBP was administered through the diet at doses of 0.45-225 ppm. We were successful in fitting the data to a probit of incidence versus log dose down to an above background liver tumor incidence of 0.02%. The model clearly demonstrates a departure from linearity at low dose, a finding that, if applicable to other models, could have a profound effect on risk assessments for regulation of chemical carcinogen exposures. ACKNOWLEDGMENTS These studies were supported by grants ES04766, ES03850, ES00210, and CA34732 from the National Institutes of Health. We also thank Greg Gonnerman,
